Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. Methods: Studi...

Full description

Saved in:
Bibliographic Details
Main Authors: Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JACC: Advances
Subjects:
alirocumab
apolipoprotein B
atherosclerotic cardiovascular disease
cholesterol
evolocumab
low-density lipoprotein
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X24008305
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items